Open science precision medicine in Canada: Points to consider
Palmira Granados Moreno,
Sarah E. Ali-Khan,
Benjamin Capps,
Timothy Caulfield,
Damien Chalaud,
Aled Edwards,
E. Richard Gold,
Vasiliki Rahimzadeh,
Adrian Thorogood,
Daniel Auld,
Gabrielle Bertier,
Felix Breden,
Roxanne Caron,
Priscilla M.D.G. César,
Robert Cook-Deegan,
Megan Doerr,
Ross Duncan,
Amalia M. Issa,
Jerome Reichman,
Jacques Simard,
Derek So,
Sandeep Vanamala,
Yann Joly
Affiliations
Palmira Granados Moreno
Centre of Genomics and Policy, Department of Human Genetics, McGill University, Montréal, QC H3A 0G1, Canada
Sarah E. Ali-Khan
Centre for Intellectual Property and Policy, Faculty of Law, McGill University, Montreal, QC H3A 1W9, Canada
Benjamin Capps
Department of Bioethics, Faculty of Medicine, Dalhousie University, Halifax, NS B3H 4R2, Canada
Timothy Caulfield
Health Law Institute, Faculty of Law and School of Public Health, University of Alberta, Edmonton, AB T6G 2H5, Canada
Damien Chalaud
Montreal Neurological Institute and Hospital, McGill University, Montreal, QC H3A 2B4, Canada
Aled Edwards
Montreal Neurological Institute and Hospital, McGill University, Montreal, QC H3A 2B4, Canada; Structural Genomics Consortium, University of Toronto, Toronto, ON M5G 1L6, Canada
E. Richard Gold
Centre for Intellectual Property and Policy, Faculty of Law, McGill University, Montreal, QC H3A 1W9, Canada
Vasiliki Rahimzadeh
Centre of Genomics and Policy, Department of Human Genetics, McGill University, Montréal, QC H3A 0G1, Canada
Adrian Thorogood
Centre of Genomics and Policy, Department of Human Genetics, McGill University, Montréal, QC H3A 0G1, Canada
Daniel Auld
McGill University and Genome Quebec Innovation Centre, Montreal, QC H3A 0G1, Canada
Gabrielle Bertier
Centre of Genomics and Policy, Department of Human Genetics, McGill University, Montréal, QC H3A 0G1, Canada
Felix Breden
Department of Biological Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada
Roxanne Caron
Centre of Genomics and Policy, Department of Human Genetics, McGill University, Montréal, QC H3A 0G1, Canada
Priscilla M.D.G. César
Centre for Intellectual Property and Policy, Faculty of Law, McGill University, Montreal, QC H3A 1W9, Canada
Robert Cook-Deegan
School for the Future of Innovation in Society, Barrett & O’Connor Washington Center, Arizona State University, Washington, DC 20006, USA
Megan Doerr
Sage Bionetworks, Seattle, WA 98109, USA
Ross Duncan
Public Health Agency of Canada, Ottawa, ON K1A 0K9, Canada
Amalia M. Issa
Centre of Genomics and Policy, Department of Human Genetics, McGill University, Montréal, QC H3A 0G1, Canada; Department of Family Medicine, McGill University, Montreal, QC H3S 1Z1, Canada; Personalized Medicine & Targeted Therapeutics, Philadelphia, PA 19803, USA; Health Policy & Pharmaceutical Sciences, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA
Jerome Reichman
School of Law, Duke University, Durham, NC 27708, USA
Jacques Simard
Genomics Center, Centre Hospitalier Universitaire de Quebec-Laval University, Quebec City, QC G1V 4G2, Canada
Derek So
Centre of Genomics and Policy, Department of Human Genetics, McGill University, Montréal, QC H3A 0G1, Canada
Sandeep Vanamala
Montreal Neurological Institute and Hospital, McGill University, Montreal, QC H3A 2B4, Canada
Yann Joly
Centre of Genomics and Policy, Department of Human Genetics, McGill University, Montréal, QC H3A 0G1, Canada
Open science can significantly influence the development and translational process of precision medicine in Canada. Precision medicine presents a unique opportunity to improve disease prevention and healthcare, as well as to reduce health-related expenditures. However, the development of precision medicine also brings about economic challenges, such as costly development, high failure rates, and reduced market size in comparison with the traditional blockbuster drug development model. Open science, characterized by principles of open data sharing, fast dissemination of knowledge, cumulative research, and cooperation, presents a unique opportunity to address these economic challenges while also promoting the public good. The Centre of Genomics and Policy at McGill University organized a stakeholders’ workshop in Montreal in March 2018. The workshop entitled “Could Open be the Yellow Brick Road to Precision Medicine?” provided a forum for stakeholders to share experiences and identify common objectives, challenges, and needs to be addressed to promote open science initiatives in precision medicine. The rich presentations and exchanges that took place during the meeting resulted in this consensus paper containing key considerations for open science precision medicine in Canada. Stakeholders would benefit from addressing these considerations as to promote a more coherent and dynamic open science ecosystem for precision medicine.
